Valeant announces combination lotion effective in treating psoriasis
Valeant Pharmaceuticals International announced positive results of a phase 3 multicenter study to measure the efficacy and safety of IDP-118 lotion, which combines halobetasol propionate and tazarotene, in treating plaque psoriasis.
IDP-118 treatment showed significance with a treatment success rate of 45.33% (P < .01) when compared with vehicle in the study of 215 adults with moderate-to-severe psoriasis, according to the release.
“We are pleased to share the positive results from the phase 3 study of this important new formulation,” Joseph C. Papa, chairman and CEO of Valeant, stated in the release. “Psoriasis is often difficult to treat and dealing with this life-long condition can significantly impact a patient's quality of life. Valeant remains committed to continued research into innovative new treatments to improve the lives of those who suffer from psoriasis.”
Halobetasol propionate and tazarotene are both approved to treat plaque psoriasis, but each can influence treatments with potential adverse events (AEs), according to the release. Existing data shows that the combination of the ingredients in IDB-118 potentially allows for an expanded use of the active ingredients with reduced AEs, the release reported.